Selecting an agent for prophylaxis of venous thromboembolism

American Journal of Health-System Pharmacy

Volumn 63, Issue 24, 2006, Pages 2448-2450

  Myers, John ^a  

^a Baptist Hospital of East Tennessee   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN;

BLEEDING; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG COST; DRUG INDICATION; DRUG SAFETY; DRUG SCREENING; DRUG USE; HOSPITALIZATION; HUMAN; LUNG EMBOLISM; MORTALITY; NOTE; PRIORITY JOURNAL; PROPHYLAXIS; VENOUS THROMBOEMBOLISM;

EID: 33847774579     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060231     Document Type: Note

References (17)

1. Cohen AT. Discoveries in thrombosis care for medical patients. Semin Thromb Hemost. 2002; 28(suppl 3):13-7.
2. Leizorovicz A, Mismetti P. Preventing venous thromboembolism in medical patients. Circulation. 2004; 110(suppl 1): IV13-9.
3. O'Connor PJ, DiBona JR. Balancing costs and outcomes through partnerships with consultants. Am J Health-Syst Pharm. 2005; 62:139-41.
4. Heit JA. The potential role of direct thrombin inhibitors in the prevention and treatment of venous thromboembolism. Chest. 2003; 124(suppl):40S-8S.
5. Sullivan SD, Kahn SR, Davidson BL et al. Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery. Pharmacoeconomics. 2003; 21:477-96.
6. Lobo BL. Pharmacoeconomic considerations. Am J Health-Syst Pharm. 2003; 60(suppl 7):S11-4.
7. Knight KK, Wong J, Hauch O et al. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized pa-tients. Value Health. 2005; 8:191-200.
8. Kaboli PJ, Brenner A, Dunn AS. Prevention of venous thromboembolism in medical and surgical patients. Cleve Clin J Med. 2005; 72(suppl 1):S7-13.
9. Siragusa S, Cosmi B, Piovella F et al. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med. 1996; 100:269-77.
10. Caro JJ, Getsios D, Caro I et al. Cost effectiveness of tinzaparin sodium versus unfractionated heparin in the treatment of proximal deep vein thrombosis. Pharmacoeconomics. 2002; 20:593-602.
11. Hull R, Raskob G, Pineo G et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med. 1993; 329:1370-6.
12. Matzsch T, Bergqvist D, Fiedin H et al. Safety and efficacy of a low molecular weight heparin (Logiparin) versus dextran as prophylaxis against thrombosis after total hip replacement. Acta Chir Scand Suppl. 1988; 543:80-4.
13. Lassen MR, Borris LC, Christiansen HM et al. Prevention of thromboembolism in 190 hip arthroplasties: comparison of LMW heparin and placebo. Acta Orthop Scand. 1991; 62:33-8.
14. Liezorovicz A, Picolet H, Peyrieux JC et al. Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double blind study comparing two doses of Logiparin and standard heparin. Br J Surg. 1991; 78:412-6.
15. Lausen I, Jensen R, Jorgensen LN et al. Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis. Eur J Surg. 1998; 164:657-63.
16. Planes A, Samama MM, Lensing AW et al. Prevention of deep vein thrombosis after hip replacement: comparison between two low-molecular-weight heparins, tinzaparin and enoxaparin. Thromb Haemost. 1999; 81:22-5.
17. Hull RD, Raskob GE, Pineo GF et al. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation: an economic perspective. Arch Intern Med. 1997; 157:298-303.